---
title: "CARsgen Therapeutics forecasts sharp reduction in annual net loss for 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273675365.md"
datetime: "2026-01-26T09:00:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273675365.md)
  - [en](https://longbridge.com/en/news/273675365.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273675365.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273675365.md) | [繁體中文](https://longbridge.com/zh-HK/news/273675365.md)


# CARsgen Therapeutics forecasts sharp reduction in annual net loss for 2025

CARsgen Therapeutics Holdings Ltd. announced a profit alert indicating an estimated reduction in loss for the year ended December 31, 2025. Based on a preliminary assessment of unaudited management accounts, the company attributes the improved business performance in part to the commercialisation of zevorcabtagene autoleucel and the acceptance of a New Drug Application (NDA). This reflects a significant positive variation compared to previous periods, as the company anticipates a narrowed loss for the reporting year. The detailed annual results are expected to be published by early March 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260126-12000885), on January 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [iShares Genomics Immnlgy & Hlthcr ETF (IDNA.US)](https://longbridge.com/en/quote/IDNA.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [WisdomTree BioRevolution ETF (WDNA.US)](https://longbridge.com/en/quote/WDNA.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [ARK Innovation ETF (ARKK.US)](https://longbridge.com/en/quote/ARKK.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [CRISPR Therapeutics AG (CRSP.US)](https://longbridge.com/en/quote/CRSP.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Franklin Genomic Advancements ETF (HELX.US)](https://longbridge.com/en/quote/HELX.US.md)

## Related News & Research

- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md)
- [InSilico Medicine Strikes Multi-Billion-Dollar AI Drug Discovery Deal With Eli Lilly](https://longbridge.com/en/news/280909399.md)
- [BUZZ-Tempus AI rises after study shows AI-driven alerts improve heart valve treatment](https://longbridge.com/en/news/281390073.md)
- [Tempus AI (TEM) Valuation Check After Daiichi Sankyo Oncology Collaboration Announcement](https://longbridge.com/en/news/281281204.md)
- [Gaudium IVF Launches AI-Led Infertility Treatment in India First](https://longbridge.com/en/news/281416110.md)